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Resting CD4+ T-cells are critical for establishing HIV-1 reservoirs. It has been known for over two decades that
resting CD4+ T-cells are refractory to HIV-1 infection, but the underlying mechanisms are not fully understood.
Compared with activated CD4+ T-cells that support HIV-1 infection, resting CD4+ T-cells have lower levels of dNTPs,
which limit HIV-1 reverse transcription. The dNTPase SAMHD1 has been identified as an HIV-1 restriction factor in
non-cycling myeloid cells. Two recent studies revealed that SAMHD1 restricts HIV-1 infection in resting CD4+ T-cells,
suggesting a common mechanism of HIV-1 restriction in non-cycling cells that may contribute to viral
immunopathogenesis.Introduction
HIV-1-induced CD4+ T-cell depletion and establishment
of viral reservoir are two hallmarks during AIDS devel-
opment. Resting CD4+ T-cells are critical for the estab-
lishment and maintenance of HIV-1 reservoirs through
multifaceted mechanisms [1]. It has been known for over
two decades that quiescent/resting CD4+ T-cells are
highly refractory to HIV-1 infection [2,3], particularly to
post-entry infection of R5-tropic, but not to X4-tropic
viruses since resting CD4+ T-cells express the HIV-1 co-
receptor CXCR4. However, the underlying mechanisms
of HIV-1 restriction in resting CD4+ T-cells are not fully
understood.
Compared with activated CD4+ T-cells that support
productive HIV-1 infection, resting CD4+ T-cells have
lower levels of dNTPs, which limit efficient HIV-1 reverse
transcription and thereby block HIV-1 infection [3].
Addition of exogenous deoxynucleotides as dNTP pre-
cursors in quiescent CD4+ T-cells only partially rescues
HIV-1 reverse transcription. The dNTP concentrations
in quiescent CD4+ T-cells (0.3–5 μM) are approxi-
mately 6–10-fold lower relative to activated CD4+ T-cells
(3–30 μM) and are around 6–100-fold higher compare
with those in non-cycling macrophages (~0.05 μM) [3,4].
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reproduction in any medium, provided the orlevels in non-cycling cells remained unclear until the
recent discovery of a host protein named SAMHD1.
SAMHD1 was initially identified as an HIV-1 restric-
tion factor in non-cycling myeloid cells, including pri-
mary monocytes, monocyte-derived dendritic cells and
macrophages [5-7]. SAMHD1 has been proposed as a
cellular regulator of the intrinsic antiviral response [8],
while its physiological role remains largely unknown.
As a dGTP-dependent deoxynucleotide triphosphohy-
drolase, SAMHD1 hydrolyzes intracellular dNTPs and
reduces their concentrations to below the levels required
for HIV-1 reverse transcription, thereby blocking viral
infection in non-cycling myeloid cells [4]. These studies
raised a significant question whether SAMHD1 contri-
butes to HIV-1 restriction in resting CD4+ T-cells. If so,
what are the implications of SAMHD1-mediated HIV-1
restriction in CD4+ T-cell depletion, establishment of
the viral reservoir, and immune evasion?
New findings and implications
Two recent studies revealed that SAMHD1 restricts
HIV-1 infection in resting CD4+ T-cells [9,10], providing
new insights into the mechanisms of HIV-1 restriction
in non-cycling cells. SAMHD1-mediated HIV-1 restric-
tion in myeloid cells has been proposed as an immune
evasion strategy for HIV-1 to avoid antiviral innate and
adaptive immune responses [5-7]. This proposed im-
mune evasion mechanism likely also exists in resting
CD4+ T-cells. In addition, HIV-1 restriction mediated
by SAMHD1 in resting CD4+ T-cells may contributeis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion and establishment of the viral reservoir and latency
(Figure 1).
Both studies by Baldauf et al. and Descours et al.
demonstrated that resting CD4+ T-cells isolated from the
peripheral blood of healthy donors express high levels of
endogenous SAMHD1 protein, which are similar to those
detected in primary myeloid cells or the monocytic THP-1
cell line [9,10]. Baldauf et al. showed that SAMHD1 is
highly expressed in explants of human tonsil and likely
localizes to non-proliferating macrophages, dendritic cellsHIV-1 





















Figure 1 SAMHD1 restricts HIV-1 infection in resting CD4+ T-cells by
triphosphohydrolase that converts intracellular dNTPs to deoxynucleosides
transcription in resting CD4+ T-cells. Treatment of resting CD4+ T-cells with
T-cells results in proteasomal degradation of SAMHD1 and leads to HIV-1 in
restriction in resting CD4+ T-cells might contribute to different aspects of v
establishment of viral reservoirs and latency. Establishing HIV-1 latency in re
actin cytoskeleton . Env, HIV-1 envelope protein.and CD4+ T-cells [9], which are the major target cell types
when HIV-1 encounters lymphoid or mucosal tissues
in vivo. Descours et al. further demonstrated that
three circulating CD4+ T-cells subsets, including naïve
(CD45RA+, CCR7+), central memory (CD45RA-, CCR7+)
and effector memory cells (CD45RA-, CCR7-), express
similarly high levels of SAMHD1 [10]. Moreover, cir-
culating CD8+ T-cells and CD19+ B-cells also express
SAMHD1 [10], although the physiologically relevant func-
tion of SAMHD1 and its regulation of dNTP levels in
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immune cell types that interact with HIV-1.
It has been shown that the lentiviral protein Vpx from
HIV-2 and sooty mangabey-lineage SIV (SIVsm) coun-
teracts SAMHD1-mediated HIV-1 restriction in mye-
loid cells through proteasomal degradation of SAMHD1
[5-7]. Similarly, Vpx from HIV-2 or SIVsm degrades
SAMHD1 in resting CD4+ T-cells and efficiently
increases single-cycle and replication-competent HIV-1
infection, which is correlated with increased products of
full-length viral cDNA and 2-LTR circles in infected cells
[9,10]. However, the degradation of SAMHD1 in resting
CD4+ T-cells by treatment of Vpx-containing virus-like
particles (VLP-Vpx) derived from SIV appears much less
efficient compared with that in primary monocytes and
activated CD4+ T-cells [10]. This might be due to dis-
tinct efficiencies of nuclear and cytoplasmic exchange
among different cell types, given that Vpx-mediated
SAMHD1 degradation is dependent on its nuclear ex-
port [11]. Furthermore, Vpx increases HIV-1 infection of
all resting CD4+ T-cell subsets (naïve, central memory
and effector memory cells) by approximately 8- to 15-
fold [10]. Importantly, VLP-Vpx treatment neither
induces CD4+ T-cell activation and proliferation nor
affects HIV-1 infection of activated CD4+ T-cells [10],
indicating that SAMHD1 specifically restricts HIV-1 in-
fection in resting CD4+ T-cells, but not in activated
CD4+ T-cells despite comparable expression levels of
endogenous SAMHD1 in these cells.
Vpx-mediated SAMHD1 degradation in resting CD4+
T-cells can only enable early steps of HIV-1 life cycle,
such as reverse transcription, but not later stages of
HIV-1 replication [9,10]. Descours et al. found that,
when SAMHD1 is degraded by Vpx in resting CD4+
T-cells, cytomegalovirus promoter-driven HIV-1 gene
expression is significantly enhanced, while HIV-1 LTR
promoter-driven viral gene expression remains blocked
despite efficient reverse transcription [10]. These results
suggest that HIV-1 transcriptional restriction in resting
CD4+ T-cells is independent of SAMHD1. By con-
trast, Baldauf et al. showed that infection of resting CD4
+ T-cells with a replication-competent HIV-1 carrying
SIV Vpx significantly enhances viral gene expression,
which is under the control of the HIV-1 LTR promoter
[9]. Notably, Descours et al. used VSV-G-pseudotyped
HIV-1 vectors in their infection assays [10], while Bal-
dauf et al. used a CXCR4-tropic replication-competent
HIV-1 [9]. Distinct envelope proteins of HIV-1 used in
these studies and/or other different experimental condi-
tions might result in the discrepancy of HIV-1 transcrip-
tional gene expression, which remains to be confirmed.
The use of VSV-G-pseudotyped HIV-1 vectors expands
the host-cell range to beyond human CD4+ T-cells, sug-
gesting that Descours et al. might examine SAMHD1function in cell types that are not necessarily relevant
to HIV-1 infection. Although Vpx treatment of resting
CD4+ T-cells enables early steps of the HIV-1 and
HIV-2 life cycle, it cannot enhance the production of
HIV-1 p24 or HIV-2 p27 capsid proteins in the super-
natants from the infected cells [9], suggesting that
addition mechanisms are involved in HIV-1 and HIV-2
restriction in resting CD4+ T-cells.
Of note, T-cell activation does not affect SAMHD1
expression levels in CD4+ T-cells [9,10]. Consistent
results were observed when CD4+ T-cell activation was
achieved either with phytohemagglutinin treatment
[9,10] or through T-cell receptor stimulation with anti-
CD3/anti-CD28 in the presence of interleukin-2 [10]. Al-
though activated CD4+ T-cells have 3- to 8-fold higher
dATP/dTTP concentrations relative to resting CD4+
T-cells, SAMHD1 expression remains the same in rest-
ing and activated CD4+ T-cells [9]. It is likely that intra-
cellular dNTP levels can be significantly increased when
activated CD4+ T-cells become dividing cells. How acti-
vated CD4+ T-cells upregulate dNTP levels without
down-regulating SAMHD1 expression remains to be
investigated. Cellular ribonucleotide reductase increases
the dNTP pool in cells through the de novo dNTP syn-
thesis pathway. Thus, it is important to analyze expres-
sion levels and the activity of ribonucleotide reductases
in resting and activated CD4+ T-cells to further under-
stand the mechanisms by which SAMHD1 regulates the
dNTP pool and HIV-1 infection efficiency in these cells.
SAMHD1 is primarily a nuclear protein [5,8] that has
a nuclear localization signal in the N-terminus [11].
Using nuclear-cytoplasmic fractionation and three-
dimensional reconstructions of confocal images, Baldauf
et al. observed that large amounts of SAMHD1 in both
the nucleus and cytoplasm of resting CD4+ T-cells, acti-
vated CD4+ T-cells, and macrophages [9], suggesting
that SAMHD1 can be a cytoplasm-nucleus shuttling
protein that depletes the dNTP pool in the cytoplasm of
resting CD4+ T-cells and macrophages where HIV-1 re-
verse transcription happens. Further microscopy studies
of SAMHD1 intracellular trafficking and its interactions
with HIV-1 particles in resting CD4+ T-cells and mye-
loid cells will help dissect the molecular details of
SAMHD1-mediated HIV-1 restriction.
Baldauf et al. showed that addition of exogenous deox-
ynucleotides in resting CD4+ T-cells or infection of rest-
ing CD4+ T-cells with Vpx-carrying HIV-1 increases the
concentrations of intracellular dATP and dTTP, which
correlates with enhanced HIV-1 infection [9]. These
results suggest that the intracellular dNTP pools in rest-
ing CD4+ T-cells are rate limiting for HIV-1 reverse
transcription, and SAMHD1 plays a regulatory role in
this process. Furthermore, silencing SAMHD1 expres-
sion in post-activated resting CD4+ T-cells using specific
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further suggesting that SAMHD1 suppresses HIV-1 in-
fection in post-activated resting CD4+ T-cells [9].
SAMHD1 gene mutations are associated with Aicardi-
Goutières syndrome (AGS), an inherited autoimmune
disease mimicking congenital viral infection with ele-
vated type I interferon production [8]. Berger et al. have
reported that, within peripheral blood mononuclear cells
(PBMCs) from SAMHD1-deficient AGS patients, CD14+
monocytes are more susceptible to HIV-1 infection com-
pared with cells from healthy donors [7]. Baldauf et al.
and Descours et al. further demonstrated that HIV-1 in-
fection of SAMHD1-deficient resting CD4+ T-cells in
PBMCs from AGS patients is significantly increased
compared with that of SAMHD1-expressing normal cells
[9,10]. Moreover, VLP-Vpx treatment of SAMHD1-
deficient resting CD4+ T-cells cannot further enhance
HIV-1 infection [10], indicating that SAMHD1 is neces-
sary for Vpx to relieve HIV-1 restriction in resting CD4+
T-cells. These ex vivo studies using SAMHD1-deficient
cells provided further evidence that SAMHD1 functions
as an HIV-1 restriction factor.
It is conceivable that SAMHD1-mediated HIV-1 re-
striction in non-cycling cells may play an important role
in viral immunopathogenesis. Doitsh et al. found that
abortive HIV-1 reverse transcription in resting tonsil
CD4+ T-cells results in cell death through proapoptotic
and proinflammatory response, which is triggered by ac-
cumulation of incomplete HIV-1 reverse transcripts [12].
However, it is unclear whether and how SAMHD1-
mediated restriction of HIV-1 in resting CD4+ T-cells
may trigger innate immune recognition of viral cDNA
and result in cell death.
Conclusions and future directions
The studies by Baldauf et al. and Descours et al.
revealed that SAMHD1 restricts HIV-1 infection in rest-
ing CD4+ T-cells by limiting viral cDNA synthesis via
depleting the intracellular dNTP pool, at least in part
[9,10]. SAMHD1-mediated HIV-1 restriction in myeloid
cells and resting CD4+ T-cells is likely a general mechan-
ism to protect host cells from productive viral infection,
which can also be a potential strategy of HIV-1 immune
evasion to avoid efficient anti-viral innate immunity [13].
Because addition of deoxynucleotides in resting CD4+
T-cells only partially restores HIV-1 reverse transcrip-
tion, other mechanisms may also contribute to HIV-1
restriction imposed by SAMHD1 in non-cycling cells. It
is possible that SAMHD1 requires a cellular cofactor in
non-cycling cells for its HIV-1 restriction function. On
the contrary, it is also plausible that T-cell activation or
myeloid cell differentiation diminishes the expression
and/or function of a SAMHD1 suppressor, thereby ren-
dering HIV-1 restriction activity of SAMHD1. Furtherstudies are needed to delineate the cellular mechanism
by which SAMHD1 inhibits HIV-1 infection in non-
cycling cells.
We have reported that polymorphisms of the
SAMHD1 gene are not associated with HIV-1 infection
and natural control in Europeans and African-
Americans [14]. It would be important to examine the
role of SAMHD1 in HIV-2 infection given that HIV-1
has not evolved a viral antagonist to SAMHD1. It is also
important to further study the effect of Vpx on SIV in-
fection and viral immunopathogenesis using SIV and
non-human primate models. SAMHD1 gene knockout
mice are currently unavailable. It would be intriguing to
examine whether SAMHD1 knockout mice mirror the
AGS symptoms in human patients and become more
susceptible to the infection with murine retroviruses or
other RNA or DNA viruses. The SAMHD1 knockout
mice will also be valuable to understand the role
SAMHD1 in innate and adaptive immunity.
Post-transcriptional regulation and/or post-translational
modifications of SAMHD1 might be important for its
function in restricting HIV-1 infection in non-cycling
cells. For example, a new study by Welbourn et al. identi-
fied naturally occurring splice variants of SAMHD1 in a
variety of cell types [15]. These splice variants do not have
the dNTPase activity and they are metabolically unstable
and therefore can be rapidly degraded in the absence of
Vpx [15], suggesting a post-transcriptional mechanism
regulating the hydrolase activity of SAMHD1.
Further elucidating the mechanisms of SAMHD1-
mediated HIV-1 restriction in non-cycling myeloid cells
and resting CD4+ T-cells may help develop new thera-
peutic approaches against HIV-1 infection. For instance,
one can use pharmacologic induction of low dNTP
pools in HIV-1 target cells to inhibit viral infection or to
block SAMHD1 activity to elicit protective anti-HIV-1
immune responses. However, these strategies likely will
be used in combination with other available anti-HIV-1
interventions and need to be carefully designed and eval-
uated to avoid potential detrimental effects on the host.
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